āagman

Not investment advice. Data and computed figures, for information only.

Corona Remedies Ltd

NSE: CORONA
₹2,044.80
−₹14.80 (−0.72%)
NSE · 15 Oct 2026, close
NSE
As of 31 Mar 2026
Market Cap
₹12,952 Cr
CMP
₹2,044.80
52-wk High / Low
₹2,292 / 1,337
P/E
61.0
P/B
17.4
Book Value
₹122.0
Div Yield
0.47%
ROCE
33.0%
ROE
29.5%
Face Value
₹10
D/E
0.22

Price+42.2% over Max

āagman read

Computed by āagman
Derived from 4 years and 8 quarters of filings. Not reported by the company.
As of 15 Oct 2026
How we compute these
Piotroski F-Score
5
/ 9
5 of 9 F-score tests passed
Graham Number
₹288
√(22.5 × EPS × book value per share)
ROIC
21.6%
vs 11.2% sector median
Cash flow to profit
1.24
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
+187
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
21.0%
ROE × earnings retention ratio
ROE stability
2.6
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom +0.00FII +1.38DII +5.88
Latest quarter vs the previous one
Cash-accrual divergence
−4.1%
of assets
Low = accruals track cash flow
Strengths
+Price trades above its 200-day moving average (1.1x)
Watch-outs

Peer comparison

Peers
NameP/EMar Cap ₹ CrROCE %ROE %

Quarterly results

Consolidated basis (as filed) · ₹ Cr · 8 quarters
As of 30 Jun 2026
Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales314298294347361342353422
Expenses247228239277283259291329
Operating Profit6769547078836293
OPM %21.3%23.2%18.4%20.2%21.6%24.3%17.6%22.0%
Other Income21222−1743
Interest32222213
Depreciation910109991013
Profit before tax5758446170555580
Net Profit4345324652414560
EPS (₹)7.037.355.167.558.556.757.419.83

Profit & Loss

As of 30 Jun 2026
Consolidated · ₹ Cr · 4 years + TTM
Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales8841,0141,1961,4031,479
Expenses7568599561,1091,162
Operating Profit128156241294317
OPM %14.5%15.4%20.2%21.0%21.4%
Other Income756−9−7
Interest4141178
Depreciation2028373842
Profit before tax111118199240260
Net Profit8590149185199
EPS (₹)13.8914.8024.4330.2732.54

Balance Sheet

As of 30 Jun 2026
Consolidated · ₹ Cr
Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026
Equity Capital61616161—
Reserves347419545686—
Borrowings2815986165—
Other Liabilities159191237293—
Total Liabilities5958319301,205—
Fixed Assets185384370554—
CWIP65121186143—
Investments32262626—
Other Assets314301348482—
Total Assets5958319301,205—

Cash Flows

As of 31 Mar 2026
Consolidated · ₹ Cr
Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity103157190229
Cash from Investing Activity−50−267−84−256
Cash from Financing Activity−4599−10725
Net Cash Flow8−110−1

Ratios

As of 31 Mar 2026
4 periods
Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %—25.032.033.0
ROE %———29.5
EPS (₹)13.8914.8024.4330.27
Book Value (₹)———122.0
Face Value (₹)———10
P/E———61.0
Div Yield %———0.47
NPM %9.58.812.413.3
OPM %14.015.020.021.0
D/E0.070.330.140.22
P/B———17.4

Growth

As of 27 Sep 2026
Compounded sales growth
3 years+17.0%
TTM+18.0%
Compounded profit growth
3 years+33.0%
TTM+28.0%
Return on equity
3 years27.0%
Last year30.0%

Shareholding pattern

As of 31 Mar 2026
Dec 2025Mar 2026
Promoters69.00%69.00%
FIIs2.25%3.63%
DIIs7.02%12.90%
Government——
Public21.75%14.47%
No. of shareholders19,60920,185
Change since Dec 2025 (pp)
Promoters +0.00FIIs +1.38DIIs +5.88Public −7.28

Documents

As of 27 Sep 2026
Announcements
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationClarification On Movement In VolumeClarification sought from Corona Remedies Ltd
Annual reports
Annual Report 2026
Credit ratings
Rating update
Concalls
Aug 2026TranscriptAug 2026PPTAug 2026RecordingMay 2026TranscriptMay 2026PPTFeb 2026TranscriptFeb 2026PPTJan 2026TranscriptJan 2026PPTJan 2026Recording

Corporate actions

As of 19 Jun 2026
19 Jun 2026DIVIDENDDividend - Rs 10 Per Share—
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman